Huizenga Theodore Alan 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Transactions
- Award
Common Stock
2025-03-01+9,392→ 51,232 total - Sale
Common Stock
2025-03-03$42.10/sh−967$40,711→ 50,265 total - Award
Stock Option (Right to Buy)
2025-03-01+5,632→ 5,632 totalExercise: $42.92Exp: 2035-03-01→ Common Stock (5,632 underlying) - Tax Payment
Common Stock
2025-03-03$42.92/sh−141$6,052→ 50,124 total
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.